Bin Jiang

US Patent:

7773224, Aug 10, 2010

Filed:

Sep 28, 2007

Appl. No.:

11/863424

Inventors:

Fan He - Gurnee IL, US
Shumin Cheng - Vernon Hills IL, US
Michael Frenzer - Palatine IL, US
Bin Jiang - Vernon Hills IL, US
Vahid Goudarzi - Coral Springs FL, US

Assignee:

Motorola, Inc. - Schaumburg IL

International Classification:

G01J 3/51

US Classification:

356425, 356402, 356406, 356419

Abstract:

A system () and method () for determining whether a sample object () has a color that is within a predetermined range is provided. The system () includes a light source () capable of projecting lights having different light wavelength spectrum upon the sample object (). A controller () causes the light source () to project a first light wavelength spectrum upon the sample object (), then another, then another, and so forth. While each light is projecting upon the object, a monochromatic image capture device () captures an image having luminous intensity information. The luminous intensity information, or a subset thereof selected by an image selection tool () is then compared to the statistical range, which is derived from a plurality of images taken of a reference object ().

US Patent:

20120231072, Sep 13, 2012

Filed:

Mar 11, 2011

Appl. No.:

13/045643

Inventors:

Eric BREY - Chicago IL, US
Victor PEREZ-LUNA - Naperville IL, US
Bin JIANG - Chicago IL, US
Pawel DRAPALA - Chicago IL, US
Hans Hitz - Arisdorf, CH
Rolf Schaefer - Arisdorf, CH

Assignee:

Chemisches Institut Schaefer AG - Bubendorf
Illinois Institute of Technology - Chicago IL

International Classification:

A61K 47/30
A61K 47/32
A61K 31/573
A61P 17/02
A61P 27/02
A61K 47/18
A61K 9/48
B82Y 5/00

US Classification:

424451, 514784, 5147726, 514180, 5147724, 5147721, 977915

Abstract:

A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having an amino acid side chain. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nanoparticle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.

US Patent:

20140065226, Mar 6, 2014

Filed:

Mar 5, 2012

Appl. No.:

13/261732

Inventors:

Eric Brey - Chicago IL, US
Victor Perez-Luna - Naperville IL, US
Bin Jiang - Chicago IL, US
Pawel Drapala - Chicago IL, US
Rolf Schäfer - Arisdorf, CH
Hans Hitz - Arisdorf, CH

International Classification:

A61K 47/32
A61K 31/573

US Classification:

424490, 5147724, 514179

Abstract:

A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having a side chain-linked amino acid. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nano-particle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.

US Patent:

20210299158, Sep 30, 2021

Filed:

Oct 11, 2018

Appl. No.:

16/755494

Inventors:

- Evanston IL, US
Jason A. Wertheim - Chicago IL, US
Bin Jiang - Evanston IL, US

Assignee:

Northwestern University - Evanston IL

International Classification:

A61K 31/727
A61K 38/08
A61K 47/54
A61K 47/64

Abstract:

Disclosed are heparin conjugates comprising heparin conjugated to a peptide that binds to a protein of the extracellular matrix (ECM) of cellular tissue, such as a collagen-binding peptide that binds to collagen of the ECM. The disclosed heparin conjugates may be utilized in methods that include treating ECM material to incorporate the heparin conjugates and impart anticoagulant activity to the ECM. The disclosed heparin conjugates also may be formulated as pharmaceutical compositions for treating and/or preventing vascular injuries and conditions.

US Patent:

20210287674, Sep 16, 2021

Filed:

Mar 15, 2021

Appl. No.:

17/202093

Inventors:

- Itasca IL, US
Wenjing Yang - Itasca IL, US
Bin Jiang - Itasca IL, US
Stephen Cradock - Itasca IL, US
Alexei Ivanov - Itasca IL, US
Fuliang Weng - Itasca IL, US
Scott Choi - Itasca IL, US

Assignee:

Knowles Electronics, LLC - Itasca IL

International Classification:

G10L 15/22
H04R 1/08
H04R 3/04
G10L 15/06
G10L 15/08

Abstract:

Various methods, systems, and apparatus are disclosed with improved imposter rejection for keyword recognition systems in a wearable device. Speech signals are measured by a microphone and a vibration sensor, the vibration sensor configured to measure vibrations in the body of a wearer of the device. An audio signal from the microphone and a vibration signal from the vibration sensor are input into a classifier to determine whether the wearer of the device spoke the keyword. In some embodiments, high-frequency components of a signal from the microphone may be combined with low-frequency components of a signal from the vibration sensor to generate a combined speech signal. The classifier may use a classification model trained with positive training data of the wearer speaking the keyword and negative training data of a non-wearer speaking the keyword.

US Patent:

20180201899, Jul 19, 2018

Filed:

Jul 15, 2016

Appl. No.:

15/744216

Inventors:

- Evanston IL, US
Bin Jiang - Evanston IL, US
Michele Jen - Dallas TX, US
Jason A. Wertheim - Evanson IL, US

International Classification:

C12N 5/071
A61K 35/44
A61K 38/50
C12N 9/80
G01N 33/50

Abstract:

Compositions comprising endothelial cells (ECs) differentiated from induced pluripotent stem cells (iPSC)that over-express Sirtuin 1 (SIRT1) are disclosed. Further disclosed are methods of preparation of the compositions, and methods for treating a subject comprising administering transplatanbe cells, tissue, or organ comprising the iPSC-derived ECs overexpressing SIRT1, as well as methods of testing an agent for therapeutic efficacy and toxicity using the compositions.

US Patent:

20170360992, Dec 21, 2017

Filed:

Dec 18, 2015

Appl. No.:

15/536860

Inventors:

- Evanston IL, US
Jason A. Wertheim - Evanston IL, US
Bin Jiang - Evanston IL, US

International Classification:

A61L 27/54
C08G 63/685
A61L 33/00
A61L 27/34
A61L 27/36
A61L 33/08
A61L 27/20
A61L 27/50
A61L 27/48
C08G 63/91
A61L 33/18

Abstract:

Provided herein are bioactivated polymer/extracellular matrix (ECM) composites and methods of preparation and use thereof. In particular, heparinized cysteine-polymer/ECM composites, and methods of preparation and use thereof, are provided. In some embodiments, provided herein are compositions comprising a composite of: (a) extracellular matrix (ECM), and (b) a polyester covalently linked to a bioactive agent. In some embodiments, the composite is a homogeneous composite. In some embodiments, the ECM is decellularized ECM. In some embodiments, the ECM is not substantially crosslinked.

US Patent:

20170087248, Mar 30, 2017

Filed:

Sep 22, 2016

Appl. No.:

15/273098

Inventors:

Eric BREY - Chicago IL, US
Victor PEREZ-LUNA - Naperville IL, US
Bin JIANG - Chicago IL, US
Christian OSSWALD - Wheeling IL, US

International Classification:

A61K 41/00
A61K 9/50
A61K 38/18
A61K 47/34
A61K 9/00
C07K 16/22
A61K 9/06
A61K 47/36

Abstract:

A hydrogel delivery composition, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent.